Utility of novel biomarkers of ‘cancer therapy-related cardiac dysfunction’ among breast cancer patients
Cancer therapy-related cardiac dysfunction (CTRCD), defined based on changes in left ventricular ejection fraction (LVEF) and cardiac biomarker levels, is a significant complication of chemotherapy, often subclinical in early stages. While conventional markers (high sensitivity cardio troponin I [hscTnI], N-termina...